Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients

Exclusion Criteria

• •Severe or unstable physical diseases judged by investigators;
• •Loss of consciousness more than 1 hour due to any reason in the past 1 year;
• •Current substance misuse (in 3 months) or any substance dependence;
• •Pregnant or lactating woman;
• •Patients with attempted suicide history, severe suicidal ideation or behaviour;
• •Mental retardation;
• •Contradict to the study drugs;
• •Patients taken other investigation products in the past 30 days before entry;
• •Patients ever taken blonanserin before;
• •Any current medical condition that would interfere with the assessment of efficacy;
• •Physical symptoms of acute deterioration requiring hospitalization or increased intensive care;
• •Significant muscle tension or Parkinson's disease;
• •Clinically significant abnormal laboratory test results (blood, urine, and blood biochemical analysis);
• •Clinically significant Abnormal electrocardiogram as judged by researchers;
• •Participants continuously using sedative drugs, or anticholinergic agents within 3 months of the study;
• •Those who had undergone electroconvulsive therapy within 3 month of the study;
• •Those who had received long-acting injection treatment within 3 month of the study;
• •Those who could not swallow medication with water;
• •Subjects judged by the investigator in charge as inappropriate for the study